NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BOCA RATON, Fla., Nov. 29,…
MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing…
With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of…
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG)…
– CEO and Founder Scott Tarriff Retires – – Chairman Michael Graves to Serve as Interim Executive Chairman – WOODCLIFF…
Turnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco AssetsBUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century…
Patient enrollment expected to begin in first half of 2024LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure…
Revenues of $2.5M, up 25% over the last two quarters of the year;Gross margin of 18.6%, up sharply on last…
Phase 1/2 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KSQ-001EX in melanoma, head and neck squamous…